Monika Ryba-Stanisławowska1, Laura Buksa2, Agnieszka Brandt3, Ulana Juhas2, Małgorzata Myśliwiec3. 1. Department of Immunology, Medical University of Gdańsk, Poland. Electronic address: akinomab@gumed.edu.pl. 2. Department of Immunology, Medical University of Gdańsk, Poland. 3. Clinic of Pediatrics, Department of Diabetology and Endocrinology, Medical University of Gdańsk, Poland.
Abstract
AIMS: The presented study was aimed to analyze the influence of IL-33 on regulatory T cells (Tregs) suppressive potential in patients with type 1 diabetes. METHODS: We analyzed the ability of IL-33 treated Tregs to inhibit the production of IFN-γ by effector T lymphocytes in an in vitro co-culture. The study group consisted of 22 patients with type 1 diabetes and 12 age and sex-matched healthy individuals. RESULTS: Our findings revealed that in vitro IL-33 treatment of Tregs derived from patients with type 1 diabetes resulted in quantitative as well as qualitative changes in this cell population, confirming immunoregulatory features of IL-33. CONCLUSION: IL-33 could be considered as a potential therapeutic tool in adoptive therapies of type 1 diabetes.
AIMS: The presented study was aimed to analyze the influence of IL-33 on regulatory T cells (Tregs) suppressive potential in patients with type 1 diabetes. METHODS: We analyzed the ability of IL-33 treated Tregs to inhibit the production of IFN-γ by effector T lymphocytes in an in vitro co-culture. The study group consisted of 22 patients with type 1 diabetes and 12 age and sex-matched healthy individuals. RESULTS: Our findings revealed that in vitro IL-33 treatment of Tregs derived from patients with type 1 diabetes resulted in quantitative as well as qualitative changes in this cell population, confirming immunoregulatory features of IL-33. CONCLUSION:IL-33 could be considered as a potential therapeutic tool in adoptive therapies of type 1 diabetes.